aim
compar
perform
molecular
nonmolecular
test
diagnos
respiratori
viral
infect
evalu
pro
contra
techniqu
method
two
hundr
ninetynin
respiratori
sampl
prospect
explor
use
multiplex
molecular
techniqu
filmarray
respiratori
panel
clart
pneumovir
immunolog
techniqu
direct
fluoresc
assay
later
flow
chromatographi
cell
cultur
find
molecular
techniqu
permit
recoveri
respiratori
pathogen
comparison
nonmolecular
method
filmarray
detect
least
pathogen
clart
pneumovir
could
explain
differ
technic
design
turnaround
time
hour
filmarray
permit
deliveri
result
patient
still
emerg
room
correspond
author
lhubulb
microbiolog
sinc
discoveri
virus
twentieth
centuri
consider
effort
made
improv
technic
detect
identifi
cell
cultur
first
diagnost
tool
use
sinc
new
techniqu
develop
decreas
time
result
immunofluoresc
later
flow
chromatographi
boost
sensit
molecular
techniqu
levin
ginocchio
harri
mani
improv
made
techniqu
combin
speed
sensit
current
avail
fulli
autom
samplein
resultout
multiplex
syndrom
molecular
tool
bluchan
ledebo
asid
effect
term
sensit
specif
latter
diagnost
tool
abl
recov
noncultiv
virus
consequ
question
regard
use
older
diagnost
method
regularli
aris
leland
ginocchio
hodinka
kaiser
meanwhil
import
question
concern
new
expens
rapid
molecular
techniqu
remain
unansw
costeffect
term
patient
manag
clinic
signific
detect
nucleic
acid
microorgan
could
noninfecti
time
sampl
collect
object
work
compar
perform
antigen
detect
cell
cultur
techniqu
routin
use
sinc
year
diagnosi
respiratori
viral
infect
set
tertiari
care
hospit
newer
molecular
techniqu
clart
pneumovir
genomica
coslada
spain
filmarray
respiratori
panel
biofir
marci
letoil
franc
studi
initi
st
februari
week
end
th
march
week
saintpierr
univers
hospit
tertiari
gener
hospit
bed
locat
downtown
brussel
peak
influenza
season
moder
belgium
last
week
week
influenza
isol
collect
belgium
http
receiv
june
receiv
revis
form
januari
accept
januari
regard
influenza
b
circul
strain
almost
exclus
victoria
lineag
accord
belgian
scientif
institut
public
health
belgian
public
health
institut
enrol
period
chosen
order
sure
gather
posit
sampl
influenza
intend
evalu
anoth
articl
impact
result
antivir
prescript
choic
obvious
affect
preval
virus
adult
children
attend
emerg
room
er
present
upper
lower
respiratori
symptom
prospect
includ
either
intend
maintain
hospit
follow
condit
known
expos
higher
rate
complic
viral
respiratori
infect
chronic
respiratori
diseas
cystic
fibrosi
asthma
sicklecel
diseas
asplenia
neuromuscular
diseas
sever
neurolog
affect
hereditari
metabol
disord
includ
diabet
congenit
acquir
immunosuppress
heart
defect
chronic
nephropathi
chronic
liver
diseas
pregnanc
children
month
age
fever
without
focu
infect
also
includ
upon
inclus
respiratori
sampl
collect
nasopharyng
aspir
npa
sampl
typic
collect
children
year
old
nasopharyng
swab
np
flock
swab
utm
ml
copan
brescia
itali
collect
older
children
adult
sampl
immedi
sent
microbiolog
laboratori
test
prior
test
npa
dilut
ml
viral
transport
medium
compos
veal
infus
broth
difco
becton
dickinson
spark
md
usa
supplement
bovin
albumin
sigma
aldrich
st
loui
mo
usa
later
flow
chromatographi
lfc
test
filmarray
respiratori
panel
use
test
sampl
wherea
direct
fluoresc
assay
dfa
cell
cultur
perform
work
hour
pm
monday
saturday
clart
pneumovir
test
perform
week
lab
result
well
clinic
data
patient
chart
record
analyz
antigen
detect
test
cell
cultur
routin
test
perform
patient
attend
emerg
depart
filmarray
clart
pneumovir
perform
studi
test
per
day
reimburs
social
welfar
combin
lfc
dfa
test
perform
vari
evalu
base
preval
circul
virus
februari
st
th
influenza
sofia
influenza
b
quidel
san
diego
ca
usa
rsv
binaxnow
rsv
aler
waltham
usa
human
metapneumoviru
hmpv
dfa
argen
marci
letoil
franc
test
perform
fiftynin
sampl
analyz
combin
februari
th
march
th
metapneumoviru
detect
replac
adenoviru
detect
test
adenorespi
kset
cori
bioconcept
gembloux
belgium
cell
cultur
perform
follow
aliquot
sampl
inocul
confluent
vero
african
green
monkey
kidney
human
lung
rhesu
monkey
kidney
cell
cultur
vircel
spain
tissu
cultur
plate
greinerbio
one
frickenhausen
germani
cultur
incub
co
atmospher
week
vero
cultur
plate
cell
week
cell
cultur
media
replac
weekli
cultur
examin
everi
two
three
day
use
invert
microscop
hemadsorpt
perform
cell
end
second
week
incub
filmarray
respiratori
panel
close
samplein
resultout
multiplex
pcr
system
integr
sampl
prepar
amplif
detect
analysi
result
approxim
hour
panel
detect
common
respiratori
virus
adenoviru
coronaviru
human
metapneumoviru
human
rhinovirusenteroviru
without
distinct
two
influenza
differenti
strain
influenza
b
parainfluenza
respiratori
syncyti
viru
rsv
panel
also
detect
bacteria
mycoplasma
pneumonia
chlamydophila
pneumonia
bordetella
pertussi
evalu
studi
test
perform
accord
manufactur
instruct
clart
pneumovir
test
microarray
techniqu
target
pathogen
filmarray
respiratori
panel
except
coronavirus
aforement
bacteria
among
enterovirus
techniqu
detect
echovirus
differenti
rhinovirus
extract
nucleic
acid
carri
qiasymphoni
system
sp
qiagen
use
qiasymphoni
virusbacteria
midi
kit
input
volum
output
volum
pneumovir
assay
perform
accord
manufactur
instruct
detect
interpret
result
conduct
carread
genomica
molecular
test
use
presum
sensit
refer
standard
viral
cultur
construct
composit
refer
standard
avoid
bia
establish
specif
evalu
test
composit
refer
standard
construct
follow
discrep
result
molecular
techniqu
observ
third
molecular
techniqu
perform
argen
marci
letoil
franc
sampl
consid
truli
posit
pathogen
least
molecular
techniqu
posit
pathogen
target
includ
filmarray
test
clart
pneumovir
panel
coronavirus
specif
posit
result
evalu
use
argen
laboratori
develop
test
data
analyz
use
two
side
exact
chisquar
fisher
test
follow
case
statist
signific
chisquar
trend
test
statist
softwar
use
medcalc
ibm
spss
total
sampl
npa
np
patient
analyz
sampl
obtain
children
femal
male
mean
age
year
month
old
median
month
old
sampl
obtain
adult
femal
male
mean
age
year
old
median
children
sampl
posit
least
one
pathogen
pathogen
detect
rang
least
rhinoenterovirus
influenza
b
influenza
coronavirus
adenoviru
metapneumoviru
rsv
parainfluenza
adult
sampl
posit
detect
virus
influenza
influenza
b
rhinoenterovirus
coronaviru
adenoviru
metapneumoviru
rsv
parainfluenza
virus
detect
adult
patient
influenza
isol
except
one
one
adult
patient
influenza
b
strain
subtyp
codetect
common
children
adult
vs
p
tabl
detail
sensit
specif
observ
differ
techniqu
depend
pathogen
tabl
provid
rate
fals
neg
result
partial
agreement
mean
least
one
expect
pathogen
detect
complet
agreement
mean
expect
pathogen
detect
nonmolecular
techniqu
molecular
techniqu
compar
establish
standard
filmarray
test
produc
fewer
fals
neg
result
partial
result
compar
nonmolecular
techniqu
clart
pneumovir
test
p
fals
neg
result
molecular
techniqu
significantli
frequent
sampl
codetect
compar
one
pathogen
vs
filmarray
test
p
vs
clart
pneumovir
test
p
similar
result
also
observ
cell
cultur
limit
analysi
cultur
virus
vs
p
tabl
report
mean
turnaround
time
tat
techniqu
recept
sampl
laboratori
introduct
result
laboratori
inform
system
lfc
filmarray
techniqu
shortest
tat
cell
cultur
clart
pneumovir
test
longest
tat
tat
neg
cell
cultur
week
discard
delay
tabl
provid
detect
rate
differ
techniqu
influenza
b
depend
durat
cough
age
patient
effect
cough
durat
influenza
antigen
detect
test
p
cell
cultur
p
due
decreas
diagnost
sensit
cough
durat
p
p
respect
decreas
observ
soon
cough
durat
exce
day
age
effect
also
observ
influenza
antigen
detect
test
p
cell
cultur
p
due
decreas
sensit
age
p
p
respect
decreas
observ
first
age
categori
antigen
detect
year
cell
cultur
effect
cough
durat
age
observ
detect
influenza
filmarray
clart
pneumovir
test
detect
influenza
b
method
expect
molecular
techniqu
observ
sensit
howev
perform
two
evalu
techniqu
differ
lower
sensit
detect
sever
target
observ
clart
pneumovir
test
notabl
techniqu
detect
echovirus
among
enterovirus
adenovirus
metapneumovirus
rsv
explan
probabl
reli
technic
consider
inde
fals
neg
result
filmarray
clart
pneumovir
test
alway
sampl
low
viral
load
indic
cycl
threshold
correl
viral
load
third
molecular
techniqu
use
elucid
discrep
result
first
two
techniqu
exampl
mean
ct
valu
standard
deviat
neg
posit
sampl
adenovirus
clart
pneumovir
respect
p
choic
primer
probe
use
design
test
determin
whether
certain
strain
viru
detect
although
filmarray
test
better
sensit
clart
pneumovir
test
detect
adenovirus
may
lack
sensit
detect
certain
strain
could
impact
manag
immunocompromis
patient
song
et
al
huge
advantag
molecular
techniqu
allow
recoveri
pathogen
difficult
cultur
grow
cultur
antigen
detect
test
avail
present
studi
rate
complet
detect
pathogen
present
sampl
far
import
molecular
techniqu
compar
nonmolecular
one
alreadi
report
weinberg
et
al
virus
poor
detect
use
nonmolecular
techniqu
primarili
includ
adenovirus
metapneumovirus
rhinoenterovirus
also
posit
sampl
coronavirus
mahoni
experi
commonli
grow
routin
cell
line
even
coronaviru
origin
describ
van
der
hoek
et
al
rate
codetect
import
children
common
find
could
explain
notabl
increas
longerlast
viral
shed
children
month
age
due
less
develop
mucos
immun
sharma
et
al
codetect
virus
children
appar
link
sever
outcom
comerlato
scotta
et
al
molecular
detect
viru
respiratori
sampl
alway
associ
symptom
type
detect
viru
age
patient
help
decid
care
plan
self
et
al
previous
state
fals
neg
result
molecular
techniqu
significantli
frequent
sampl
multipl
pathogen
compar
one
pathogen
find
could
due
possibl
competit
reagent
multipl
target
detect
bezerra
et
al
specif
molecular
techniqu
except
rhinoenterovirus
filmarray
test
differ
observ
molecular
techniqu
could
also
due
primer
probe
choic
overal
clart
pneumovir
less
sensit
filmarray
except
influenza
b
handson
time
turnaround
time
longer
posit
sampl
analyz
metapneumoviru
use
antigen
detect
test
substitut
adenoviru
test
evalu
test
nonetheless
appear
sensit
cell
cultur
test
metapneumoviru
recov
cell
cultur
find
expect
sensit
approxim
accord
literatur
tang
crow
appar
low
sensit
nonmolecular
techniqu
observ
adenovirus
deserv
comment
inde
prolong
shed
primari
infect
classic
describ
adenoviru
adenovirus
also
detect
tonsillar
tissu
isol
throat
sampl
healthi
children
song
et
al
kalu
et
al
state
prolong
shed
latenc
like
detect
molecular
techniqu
also
noteworthi
adenovirus
detect
evalu
associ
one
pathogen
support
hypothesi
could
bystand
case
sensit
cell
cultur
rhinoenteroviru
also
low
could
partial
attribut
fact
group
c
rhinovirus
grow
standard
cell
cultur
jacob
et
al
enterovirus
grow
inconsist
cell
cultur
depend
type
cell
line
enabl
detect
strain
stellrecht
et
al
unfortun
rhinovirus
enterovirus
studi
type
presenc
multipl
virus
sampl
also
influenc
cultur
growth
fitter
abund
viru
mask
growth
other
georg
et
al
exampl
fals
neg
cultur
rhinoenterovirus
posit
anoth
viru
likewis
adenovirus
fals
neg
cell
cultur
recov
anoth
viru
molecular
techniqu
supposedli
suffer
drawback
although
previous
discuss
higher
rate
fals
neg
observ
multipl
pathogen
present
sampl
cell
cultur
howev
enabl
detect
unsuspect
virus
detect
case
evalu
one
measl
viru
origin
suspect
herp
simplex
virus
cytomegalovirus
cmv
one
case
cmv
could
explain
symptom
exhibit
patient
fever
without
focu
infect
case
like
recurr
prolong
shed
regard
sensit
antigen
detect
test
influenza
influenza
easili
detect
influenza
b
alreadi
report
busson
et
al
decreas
sensit
influenza
antigen
detect
cell
cultur
depend
age
patient
explain
higher
viral
shed
children
also
younger
children
npa
prefer
np
aspir
usual
increas
detect
rate
virus
swab
loen
et
al
decreas
sensit
antigen
detect
cell
cultur
durat
cough
increas
expect
viral
shed
import
first
day
diseas
aoki
boivin
reason
lack
similar
find
influenza
b
unclear
absenc
sensit
loss
molecular
techniqu
depend
age
patient
durat
cough
attribut
high
sensit
techniqu
usual
antigen
detect
test
faster
turnaround
time
cell
cultur
lower
sensit
except
virus
grow
poorli
especi
metapneumoviru
rsv
sensit
antigen
detect
test
better
one
cell
cultur
specif
nonmolecular
test
fals
posit
result
cell
cultur
occur
due
crosscontamin
well
cultur
plate
antigen
detect
test
base
later
flow
chromatographi
usual
easiest
fastest
perform
techniqu
base
immunofluoresc
slightli
timeconsum
current
total
autom
techniqu
short
handson
time
filmarray
realiz
time
frame
compar
lfc
test
howev
one
perform
one
time
analyz
remain
occupi
slightli
hour
number
requir
instrument
base
test
volum
facil
desir
tat
cell
cultur
remain
timeconsum
techniqu
result
often
arriv
late
impact
patient
manag
ginocchio
also
case
clart
pneumovir
set
perform
week
due
complex
correspond
analyt
process
belgium
nonmolecular
techniqu
diagnosi
respiratori
virus
reimburs
social
welfar
program
case
molecular
techniqu
charg
patient
evalu
molecular
techniqu
free
charg
patient
cost
approxim
euro
per
patient
necess
molecular
test
must
serious
consid
prescript
test
probabl
reserv
sever
ill
patient
rapid
comprehens
microbiolog
evalu
like
impact
patient
manag
comparison
antigen
detect
test
cost
includ
workforc
rang
euro
depend
test
cell
cultur
cost
euro
howev
nonmolecular
test
reimburs
social
welfar
belgium
permit
broader
prescript
possibl
implement
molecular
test
vari
facil
countri
depend
local
polici
use
molecular
rather
nonmolecular
techniqu
could
impact
patient
isol
strategi
richardson
et
al
antibioticantivir
use
reduc
length
stay
brendish
et
al
roger
et
al
costbenefit
analys
difficult
apprais
mani
intertwin
element
molecular
techniqu
consider
increas
capac
detect
respiratori
virus
time
manner
main
factor
limit
wide
util
techniqu
cost
difficulti
absorb
workload
larg
facil
numer
sampl
analyz
per
day
anoth
drawback
latent
virus
trace
genet
materi
may
detect
interpret
posit
result
might
difficult
must
care
correl
clinic
histori
patient
presenc
viru
respiratori
tract
factor
expos
bacteri
superinfect
vareil
et
al
possibl
quantifi
viral
load
respiratori
sampl
conflict
report
regard
correl
viral
load
outcom
granado
et
al
wishaupt
et
al
technic
improv
made
prevent
variat
quantif
caus
sampl
dilut
salin
instil
aspir
variabl
quantiti
sampl
materi
swab
improv
could
render
comparison
studi
reliabl
permit
establish
threshold
detect
virus
inde
involv
ongo
infecti
process
addit
posit
antigen
detect
test
usual
correl
high
viral
load
sampl
posit
cell
cultur
achiev
infect
viral
particl
whatev
techniqu
use
fulli
understand
benefit
limit
crucial
interpret
choic
techniqu
depend
besid
financi
consider
necessari
sensit
speed
base
symptom
comorbid
risk
detriment
outcom
patient
tertiari
care
hospit
abl
offer
diagnost
tool
suitabl
individu
case
test
patient
molecular
techniqu
possibl
use
nonmolecular
techniqu
prefer
noth
